Benitec Biopharma Inc.
BNTC
$12.37
-$0.63-4.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -0.83% | -32.04% | 44.48% | -11.35% | -51.81% |
| Total Depreciation and Amortization | -0.83% | 1.69% | 0.00% | 11.32% | 30.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.89% | 42.45% | -61.49% | 73.70% | 226.20% |
| Change in Net Operating Assets | -140.57% | 77.85% | 105.61% | -258.06% | 688.28% |
| Cash from Operations | -17.90% | -12.68% | 59.20% | -166.14% | 59.94% |
| Capital Expenditure | -36.36% | -- | -- | 100.00% | 50.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -36.36% | -- | -- | 100.00% | 50.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.51% | -- | -- | 39.02% | 70.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.98% | -- | -- | -1,672.87% | -112,150.00% |
| Cash from Financing | -99.48% | -- | -- | -90.98% | 57.88% |
| Foreign Exchange rate Adjustments | 49.24% | -253.49% | 171.67% | -471.43% | -107.37% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -104.27% | 2,988.55% | 43.60% | -123.06% | 140.43% |